GEXVal Invited to Connect to Australia Forum in Boston

株式会社GEXVal
June 2, 2025

GEXVal Invited to Exclusive Connect to Australia Biotech Ecosystem Forum

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that Dr. Juran Kato has been invited to participate in "Connect to Australia," an exclusive forum hosted by the South Australian and Western Australian governments in conjunction with BIO International 2025 in Boston.

GEXVal has completed Phase I and Proof of Mechanism (PoM*) trials in Australia through its subsidiary GEXVal AU Pty Ltd, pioneering the use of Australia's efficient clinical development pathway among Japanese biopharmas.

Trials Registry (ANZCTR, Registration number: ACTRN12622000743763).
https://www.anzctr.org.au/TrialSearch.aspx

Keiichi Kiyota, Chief Financial Officer, commented: "This invitation-only forum represents rare participation by a Japanese company. We are honored that our track record of rapid, value-creating clinical development in Australia and our contributions to Japan-Australia bio ecosystem cooperation have earned international recognition. This participation strengthens our relationship with the Australian government and solidifies our position within the local ecosystem as we prepare to initiate Phase II trials."

**Event Overview**

This exclusive forum brings together selected global biotech companies to explore Australia's rapidly growing biotech ecosystem, distinguished by its streamlined regulatory environment, world-class research institutions, strategic access to the Asia-Pacific region, and robust government R&D support.

*About PoM (Proof of Mechanism)
A study that confirms target engagement—scientifically demonstrating that a drug interacts with its intended molecular target. PoM trials measure and verify molecular-level or systemic physiological indicators resulting from the drug's pharmacological action.

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

有关本事宜请咨询:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com